In contrast to the previous year's interim dividend of Rs 7.50 per share, the company's board has declared an interim dividend of Rs 8.50 per share for FY24.
The company's managing director, Dilip Shanghvi, stated, "We are happy with our continuous broad-based expansion, which includes Global Specialty. We eagerly anticipate Nidlegy's EMA filing in the upcoming months. Nidlegy will greatly increase our onco-derm franchise in Europe if it is approved."
In India, sales of formulations accounted for approximately 31% of overall sales in Q3 FY24, with sales of Rs 3,778.5 crore, up 11.4%.
In the United States, formula sales reached $477 million, representing a 13.2% gain and more than 33% of total sales.
Active pharmaceutical ingredients (API) saw a 9.6% decrease in external sales to Rs 466.1 crore during the third quarter of FY24. The pharmaceutical behemoth stated, "We continue to focus on increasing API supply for captive consumption for key products."
The stock surged 4.88 percent to reach Rs 1,438.50, the level of its one-year high.
